Hotsia.Com : เที่ยวสะใจ

How does home medication reconciliation catch duplicate RAAS/diuretic therapy in CKD, what safety studies show, and how does this compare with clinic-only review?

Home medication reconciliation, particularly when performed by a pharmacist or nurse, is a crucial process for identifying and correcting medication discrepancies, including duplicate therapies. In patients with Chronic Kidney Disease (CKD), this is especially vital as they are often on a complex regimen of drugs, including those that act on the Renin-Angiotensin-Aldosterone System (RAAS) and diuretics, which can cause harm if duplicated. Home-based review provides a unique opportunity to directly inspect the patient’s medication cabinet, revealing all drugs they are actually taking, including over-the-counter (OTC) medications, supplements, and prescriptions from multiple providers that may not be in their primary medical record. This physical inspection, combined with a detailed conversation with the patient and/or caregiver, helps uncover duplicate prescriptions that may have been issued by different specialists or refills from a prior prescription, something often missed in a clinic setting. For example, a patient might be prescribed an Angiotensin-Converting Enzyme (ACE) inhibitor by their nephrologist and an Angiotensin Receptor Blocker (ARB) by their cardiologist, leading to a dangerous dual RAAS blockade that increases the risk of hyperkalemia and acute kidney injury. A home review can catch this by seeing both bottles in the patient’s possession.

🏥 The Revelations of Safety Studies

Safety studies, particularly those involving pharmacists in a home or transitional care setting, have consistently shown that medication reconciliation can significantly reduce medication-related problems (MRPs) and potential for harm. While the evidence on its direct impact on major clinical outcomes like hospital readmissions and mortality is somewhat mixed, the data on its ability to identify and resolve discrepancies is strong. Randomized controlled trials (RCTs) and systematic reviews have demonstrated that medication reconciliation, especially when led by a pharmacist, identifies a high number of unintentional discrepancieswith some studies finding discrepancies in nearly all patients. A common discrepancy is the omission of a necessary medication, but a significant proportion are duplications or incorrect dosages. For CKD patients on RAAS inhibitors and diuretics, this is a major safety issue. Duplicate therapy can lead to an increased risk of severe hypotension and electrolyte abnormalities, particularly hyperkalemia, which can be life-threatening. By identifying these duplications, a home-based reconciliation helps prevent these adverse drug events. Studies often find that pharmacists identify and resolve these discrepancies at a higher rate than other healthcare providers. For instance, a systematic review on interventions during care transitions found that pharmacist-led medication reconciliation was a key component of successful programs that reduced medication errors. The evidence is clear that while the overall impact on hospitalization might be subtle, the ability to prevent specific, high-risk medication errors is a substantial patient safety benefit.

⚖️ Home-Based Review vs. Clinic-Only Review

The fundamental difference between home-based medication reconciliation and a clinic-only review lies in the completeness of the medication list and the direct observation of patient behaviors. A clinic-only review relies heavily on what the patient and their family can remember and what is documented in a single electronic health record (EHR). This approach is often incomplete. Patients may forget to mention over-the-counter medications, herbal supplements, or even prescriptions filled from a different pharmacy or given by a different specialist that isn’t connected to the primary clinic’s EHR. In contrast, a home-based review allows a healthcare professional to see exactly what the patient has, including those medications from other sources, old prescriptions that haven’t been discontinued, and supplements not documented elsewhere. This direct observation is critical for catching duplicate RAAS/diuretic therapy. For example, a patient might have a prescription for a diuretic like furosemide from their primary care physician for heart failure and another for hydrochlorothiazide from their nephrologist for hypertension, both of which may not be in a single EHR. A home visit reveals both bottles. Additionally, a home visit allows the healthcare provider to assess adherence, understanding, and storage of medications, offering a more holistic view of the patient’s medication use. While clinic reviews are a necessary part of routine care, they often provide only a partial picture. The comprehensive nature of a home review, with its ability to physically verify every medication the patient is taking, gives it a significant advantage in catching subtle but dangerous discrepancies like duplicate RAAS/diuretic therapy, which can be particularly harmful to the delicate balance of fluid and electrolytes in a patient with CKD. This is why many transitional care models are incorporating home visits, particularly for high-risk patients with polypharmacy.

 

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com